You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

FLORBETABEN F-18 - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for florbetaben f-18 and what is the scope of patent protection?

Florbetaben f-18 is the generic ingredient in one branded drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Florbetaben f-18 has thirty-five patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for FLORBETABEN F-18
International Patents:35
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 5
Clinical Trials: 24
Patent Applications: 239
DailyMed Link:FLORBETABEN F-18 at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FLORBETABEN F-18
Generic Entry Date for FLORBETABEN F-18*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FLORBETABEN F-18

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of PennsylvaniaPhase 3
National Institutes of Health (NIH)Phase 3
Life Molecular Imaging GmbHPhase 3

See all FLORBETABEN F-18 clinical trials

Pharmacology for FLORBETABEN F-18

US Patents and Regulatory Information for FLORBETABEN F-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Life Molecular NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for FLORBETABEN F-18

Country Patent Number Title Estimated Expiration
New Zealand 555942 Radiolabelled tilbene derivatives and their use for binding and imaging amyloid plaques ⤷  Sign Up
Israel 183946 STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES ⤷  Sign Up
Slovenia 2213652 ⤷  Sign Up
Eurasian Patent Organization 200701299 ПРОИЗВОДНЫЕ СТИЛЬБЕНА И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for FLORBETABEN F-18

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213652 122015000018 Germany ⤷  Sign Up PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
2213652 504 Finland ⤷  Sign Up
2213652 1590005-3 Sweden ⤷  Sign Up PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906 20140224
2213652 132015902339134 Italy ⤷  Sign Up PRODUCT NAME: FLORBETABEN (18)(NEURACEQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/906, 20140224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.